Miriam Sartages

Ms. Miriam Sartages

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
MSMiriam Sartages
Miriam Sartages
MGMar García-Colomer
Mar García-Colomer
CICristina Iglesias
Cristina Iglesias
BHBrian W. Howell
Brian W. Howell
MMManuel Macía
Manuel Macía
JZJuan Zalvide
Juan Zalvide
Background: Cavernous cerebral malformations can arise because of mutations in the CCM1, CCM2, or CCM3 genes, and lack of Cdc42 has also been reported to induce these malformations in mice. However, the role of the CCM3 (cerebral cavernous malformation 3)-associated kinases in cavernoma development is not known, and we, therefore, have investigated their role in the process. Methods: We used a combination of an in vivo approach, using mice genetically modified to be deficient in the CCM3-associated kinases STK24 and STK25 (serine/threonine kinases 24 and 25), and the in vitro model of human endothelial cells in which expression of STK24 and STK25 was inhibited by RNA interference. Results: Mice deficient for both Stk24 and Stk25, but not for either of them individually, developed aggressive vascular lesions with the characteristics of cavernomas at an early age. Stk25 deficiency also gave rise to vascular anomalies in the context of Stk24 heterozygosity. Human endothelial cells deficient for both kinases phenocopied several of the consequences of CCM3 loss, and single STK25 deficiency also induced KLF2 expression, Golgi dispersion, altered distribution of β-catenin, and appearance of stress fibers. Conclusions: The CCM3-associated kinases STK24 and STK25 play a major role in the inhibition of cavernoma development. Download figure Download PowerPoint

17 December 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
MSMiriam Sartages
Miriam Sartages
EFEbel Floridia
Ebel Floridia
MGMar García-Colomer
Mar García-Colomer
CICristina Iglesias
Cristina Iglesias
MMManuel Macia-Cortiñas
Manuel Macia-Cortiñas
JZJuan Zalvide
Juan Zalvide
Cerebral cavernous malformations (CCMs) are vascular malformations that can be the result of the deficiency of one of the CCM genes. Their only present treatment is surgical removal, which is not always possible, and an alternative pharmacological strategy to eliminate them is actively sought. We have studied the effect of the lack of one of the CCM genes, CCM3, in endothelial and non-endothelial cells. By comparing protein expression in control and CCM3-silenced cells, we found that the levels of the Epidermal Growth Factor Receptor (EGFR) are higher in CCM3-deficient cells, which adds to the known upregulation of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) in these cells. Whereas VEGFR2 is upregulated at the mRNA level, EGFR has a prolonged half-life. Inhibition of EGFR family members in CCM3-deficient cells does not revert the known cellular effects of lack of CCM genes, but it induces significantly more apoptosis in CCM3-deficient cells than in control cells. We propose that the susceptibility to tyrosine kinase inhibitors of CCM3-deficient cells can be harnessed to kill the abnormal cells of these lesions and thus treat CCMs pharmacologically.

9 July 2026 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
MGMar García‐Colomer
Mar García‐Colomer
JRJose Emilio Martinez Rodrigruez
Jose Emilio Martinez Rodrigruez
LDLuis Diaz-Gomez
Luis Diaz-Gomez
MSMiriam Sartages
Miriam Sartages
EEEva M. Esquinas‐Román
Eva M. Esquinas‐Román
JZJuan Zalvide
Juan Zalvide
This study investigates the impact of rapamycin and propranolol on cerebral cavernous malformations (CCMs). Employing an unbiased transcriptomic analysis, we aimed to comprehensively elucidate the molecular mechanisms underlying these drug effects. Mouse Brain Microvascular Endothelial Cells (mBMEC) deficient in Ccm3 were treated with propranolol or rapamycin and were analysed by RNA‐seq and immunofluorescence. While propranolol shows limited efficacy in modulating the CCM transcriptomic phenotype in mBMEC, rapamycin demonstrates a significant impact. Rapamycin partially reverses gene expression changes induced by Ccm3 deficiency, restoring KLF2/4‐dependent genes like Nos3, Adamts1, and Thbs1. Notably, we observed a reduction in KLF2 protein levels in Ccm3 KO cells treated with rapamycin. We also sought to determine whether rapamycin, especially in combination with the tyrosine kinase inhibitor lapatinib, which induces proapoptotic gene expression in Ccm3‐deficient endothelium, can reduce lesion volume even after lesion growth has occurred. Ccm3 iEC mice in which cavernoma development had been induced were treated with rapamycin alone or combined with lapatinib, assessing lesion volume using micro‐CT imaging. Notably, a combination of rapamycin and lapatinib effectively reduces lesion volume in a chronic CCM model. In summary, our work reveals a mechanism by which rapamycin modulates Ccm3 KO endothelial cells and identifies rapamycin plus lapatinib as a possible combination therapy for cavernomas.

5 November 2025 in bioRxiv
Verified
Preprint
Open access
MGMar García-Colomer
Mar García-Colomer
JMJosé E Martínez
José E Martínez
LDLuis Diaz-Gomez
Luis Diaz-Gomez
MSMiriam Sartages
Miriam Sartages
EEEva M. Esquinas-Román
Eva M. Esquinas-Román
JZJuan Zalvide
Juan Zalvide
This study investigates the impact of rapamycin and propranolol on cerebral cavernous malformations (CCMs). Employing an unbiased transcriptomic analysis, we aimed to comprehensively elucidate the molecular mechanisms underlying these drug effects in Mouse Brain Microvascular Endothelial Cells (mBMEC) deficient in Ccm3 . While propranolol shows limited efficacy in modulating the CCM transcriptomic phenotype in mBMEC, rapamycin demonstrates a higher impact. Rapamycin reverses gene expression changes induced by Ccm3 deficiency, restoring Klf2/4 -dependent genes like Nos3 , Adamts1 , and Thbs1 . Notably, we observed a reduction in KLF2 protein levels in Ccm3 KO cells treated with rapamycin. Critically, in vivo experiments demonstrate that a combination of rapamycin and lapatinib effectively reduces lesion volume in a chronic CCM model. This finding is particularly noteworthy as it suggests a potential treatment strategy for existing lesions. In summary, our work describes a new mechanism for the effects of rapamycin in Ccm3 - deficient cells and identifies a new drug combination in the treatment of cavernomas.